GlassScriptPhysician profile
Charles Oliner
NPI 1740449313
$4,901.80
in general payments reported to CMS, 2019-2025
18 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.89 · 2020: $443 · 2021: $482 · 2022: $808 · 2023: $953 · 2024: $978 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,220.83 | 2019-2025 | Xifaxan, Plenvu |
| Abbvie INC. | $774.53 | 2019-2025 | |
| Celgene Corporation | $379.24 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $291.12 | 2024-2025 | Voquezna |
| Allergan, INC. | $235.60 | 2020 | |
| Redhill Biopharma INC. | $215.49 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Gilead Sciences, INC. | $187.13 | 2021-2024 | |
| Janssen Biotech, INC. | $126.54 | 2022-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $117.06 | 2025 | Ibsrela |
| Madrigal Pharmaceuticals | $72.45 | 2025 | Rezdiffra |
| Capsovision, INC. | $64.98 | 2023-2024 | Capsocam Plus |
| Exact Sciences Corporation | $61.97 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Braintree Laboratories, INC. | $53.44 | 2021-2023 | Suflave, Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $27.37 | 2025 | Entyvio |
| Ipsen Biopharmaceuticals, INC | $24.78 | 2025 | Iqirvo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.08 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $13.39 | 2020 | |
| Daiichi Sankyo INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Oliner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.